Could you elaborate on the reasons behind the discontinuation of oxymorphone? Was it due to safety concerns, a lack of efficacy, or perhaps regulatory changes? Understanding the specific factors that led to its withdrawal from the
market would provide valuable insight into the decision-making process and its potential implications for patients and healthcare professionals.
6 answers
CryptoBaroness
Mon Sep 16 2024
In 2012, Endo Pharmaceuticals made a significant change to their Opana ER product by introducing a new formulation. This move was prompted by the company's desire to address safety concerns associated with the original version of the drug.
Giulia
Mon Sep 16 2024
As part of this transition, Endo petitioned the relevant agency to officially acknowledge that the original Opana ER formulation had been withdrawn from the market due to these safety concerns.
noah_stokes_photographer
Mon Sep 16 2024
The withdrawal of the original Opana ER formulation had far-reaching implications, as it also meant that any generic products that were referencing or based on the original formulation would also need to be removed from the market.
SumoPowerful
Sun Sep 15 2024
The decision to replace the original Opana ER formulation with a new one was not taken lightly. It required careful consideration and analysis of the safety data available at the time.
Elena
Sun Sep 15 2024
The new formulation of Opana ER was designed to address the safety concerns that had been raised about the original version. It aimed to provide a safer and more effective treatment option for patients.